Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.78 Insider Own6.71% Shs Outstand81.63M Perf Week-2.50%
Market Cap1.99B Forward P/E- EPS next Y-4.77 Insider Trans-16.34% Shs Float76.79M Perf Month13.28%
Income-134.74M PEG- EPS next Q-1.14 Inst Own78.60% Short Float18.99% Perf Quarter-46.26%
Sales360.91M P/S5.52 EPS this Y-175.80% Inst Trans-0.68% Short Ratio10.15 Perf Half Y-18.37%
Book/sh11.10 P/B2.18 EPS next Y-0.51% ROA-10.01% Short Interest14.58M Perf Year-24.81%
Cash/sh13.30 P/C1.82 EPS next 5Y-3.70% ROE-16.09% 52W Range16.95 - 49.50 Perf YTD-11.02%
Dividend Est.- P/FCF- EPS past 5Y5.58% ROI-12.60% 52W High-51.07% Beta1.89
Dividend TTM- Quick Ratio5.99 Sales past 5Y43297.50% Gross Margin92.92% 52W Low42.89% ATR (14)1.40
Dividend Ex-DateFeb 04, 2014 Current Ratio5.99 EPS Y/Y TTM60.93% Oper. Margin-50.34% RSI (14)48.40 Volatility4.58% 5.84%
Employees436 Debt/Eq0.18 Sales Y/Y TTM370.57% Profit Margin-37.33% Recom1.93 Target Price48.38
Option/ShortYes / Yes LT Debt/Eq0.17 EPS Q/Q9.51% Payout- Rel Volume0.53 Prev Close24.32
Sales Surprise-56.63% EPS Surprise14.50% Sales Q/Q-69.39% EarningsMay 07 BMO Avg Volume1.44M Price24.22
SMA204.08% SMA50-9.14% SMA200-9.11% Trades Volume755,102 Change-0.41%
Date Action Analyst Rating Change Price Target Change
Jan-29-24Upgrade JP Morgan Neutral → Overweight $38 → $40
Dec-15-23Downgrade BofA Securities Buy → Neutral $35
Dec-08-23Downgrade Jefferies Buy → Hold $75 → $30
Oct-20-23Downgrade Leerink Partners Outperform → Market Perform $75 → $20
Oct-20-23Downgrade Cantor Fitzgerald Overweight → Neutral
Mar-21-23Initiated Bernstein Mkt Perform $37
Feb-01-23Initiated Cantor Fitzgerald Overweight $62
Dec-20-22Upgrade BMO Capital Markets Market Perform → Outperform $61 → $66
Dec-13-22Initiated Citigroup Buy $62
Jun-17-22Initiated BMO Capital Markets Market Perform $41
May-14-24 04:00PM
May-13-24 02:18PM
May-09-24 06:49AM
May-08-24 10:52AM
09:02PM Loading…
May-07-24 09:02PM
May-01-24 10:01AM
Mar-28-24 11:30AM
Mar-26-24 06:30AM
Feb-28-24 06:30AM
Feb-27-24 04:01PM
12:33PM Loading…
Feb-20-24 10:00AM
Feb-16-24 02:46PM
Feb-10-24 05:09PM
Feb-07-24 07:35AM
Feb-05-24 06:30AM
Jan-29-24 06:21PM
Jan-16-24 01:51PM
Jan-11-24 04:38PM
Jan-08-24 06:30AM
Jan-02-24 06:30AM
10:30AM Loading…
Dec-27-23 10:30AM
Dec-15-23 10:22AM
Dec-14-23 06:30AM
Dec-08-23 11:30AM
Nov-30-23 09:55AM
Nov-23-23 11:03AM
Nov-20-23 05:43PM
Nov-18-23 07:15AM
Nov-17-23 12:00PM
Nov-14-23 05:50AM
Nov-10-23 09:55AM
Nov-09-23 01:04PM
Nov-08-23 06:30AM
Nov-06-23 08:02AM
Nov-05-23 08:30AM
Nov-01-23 05:40AM
Oct-31-23 07:09PM
Oct-30-23 03:46PM
Oct-27-23 07:15AM
Oct-25-23 06:30AM
Oct-21-23 08:45AM
Oct-20-23 11:43AM
Oct-19-23 09:03AM
Oct-18-23 09:30AM
Oct-05-23 08:45AM
Oct-03-23 06:27AM
Sep-29-23 10:30AM
Sep-27-23 08:30AM
Sep-22-23 05:50AM
Sep-08-23 08:20AM
Sep-07-23 10:00AM
Sep-05-23 06:30AM
Aug-31-23 07:37AM
Aug-26-23 07:50AM
Aug-19-23 05:52AM
Aug-13-23 09:28AM
Aug-11-23 09:35AM
Aug-08-23 07:40AM
Jul-15-23 03:45PM
Jul-09-23 10:23AM
Jun-18-23 05:52AM
Jun-15-23 08:22AM
May-21-23 08:23AM
May-17-23 06:30AM
May-16-23 05:50AM
May-11-23 06:30AM
May-10-23 07:45AM
May-02-23 12:25PM
Apr-28-23 04:51PM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Simon AmyChief Medical OfficerApr 02 '24Sale30.5416,530504,85170,060Apr 03 07:43 PM
Evans John M.CEOApr 01 '24Sale32.1318,102581,6171,058,343Apr 03 07:36 PM
Simon AmyChief Medical OfficerApr 01 '24Sale32.137,157229,95486,590Apr 03 07:43 PM
Burrell Terry-AnnChief Financial OfficerApr 01 '24Sale32.125,446174,92670,137Apr 03 07:39 PM
Ciaramella GiuseppePresidentApr 01 '24Sale32.124,534145,632169,616Apr 03 07:33 PM
Bellon ChristineChief Legal OfficerApr 01 '24Sale32.123,401109,240104,594Apr 03 07:40 PM
Evans John M.CEOMar 28 '24Sale33.8660,0002,031,402998,262Apr 01 04:10 PM
FMR LLCSee Remark 1Feb 14 '24Sale30.55900,00027,496,9121,235,511Feb 15 02:34 PM
FMR LLCSee Remark 1Feb 13 '24Sale30.761,56548,1392,771,913Feb 15 02:34 PM
Evans John M.CEOJan 31 '24Sale25.3360,0001,519,8001,058,262Feb 02 04:05 PM
Bellon ChristineChief Legal OfficerJan 03 '24Sale26.421,90750,38380,495Jan 05 04:30 PM
Bellon ChristineChief Legal OfficerNov 20 '23Option Exercise7.2210,00072,20092,402Nov 22 04:05 PM
Bellon ChristineChief Legal OfficerNov 20 '23Sale30.5010,000305,00082,402Nov 22 04:05 PM
Simon AmyChief Medical OfficerOct 30 '23Sale18.703,44864,47865,469Nov 01 04:30 PM
Ciaramella GiuseppePresident and CSOOct 20 '23Option Exercise0.6790,90060,903139,150Oct 24 04:05 PM
Bellon ChristineChief Legal OfficerOct 02 '23Sale22.853888,86682,402Oct 04 04:30 PM
Ciaramella GiuseppePresident and CSOJul 24 '23Option Exercise7.221,2068,70749,456Jul 25 06:36 PM
Ciaramella GiuseppePresident and CSOJul 24 '23Sale32.011,20638,60448,250Jul 25 06:36 PM
Ciaramella GiuseppePresident and CSOJul 21 '23Option Exercise7.2291,284659,070203,574Jul 25 06:36 PM
Ciaramella GiuseppePresident and CSOJul 21 '23Sale32.06155,3244,979,68748,250Jul 25 06:36 PM
Simon AmyChief Medical OfficerJul 10 '23Sale30.4839111,91868,917Aug 09 04:08 PM